VRTX · Vertex Pharmaceuticals Incorpor
$517.49
-1.23% last session
End-of-day data · close of 2026-10-26
Market cap
$133B
Enterprise value
$127B
Trailing P/E
29.9
Forward P/E
25.7
Dividend yield
0.0%
Beta
0.28
Avg volume
1M
Employees
6K
Daily Change %
-1.23%
5 Days Change
7.09%
10 Days Change
10.29%
30 Days Change
3.65%
60 Days Change
-2.27%
Month to Day Change
5.61%
Year to Day Change
18.05%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VRTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-08
Latest call per bank · past 12 months
RBC Capital
Outperform$576
+9.9% vs priceUBS
Buy$615
+17.4% vs priceBarclays
Overweight$617
+17.8% vs priceMorgan Stanley
Overweight$616
+17.6% vs priceBank of America
Buy$598
+14.1% vs priceCitigroup
Buy$585
+11.7% vs priceJefferies
Buy$580
+10.7% vs priceWells Fargo
Overweight$515
-1.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Maintains | Outperform | $570 → $576 |
| 2026-09-28 | UBS | Maintains | Buy | $585 → $615 |
| 2026-08-05 | Truist Securities | Maintains | Buy | $560 → $565 |
| 2026-08-05 | Barclays | Maintains | Overweight | $615 → $617 |
| 2026-08-04 | TD Cowen | Maintains | Buy | $525 → $550 |
| 2026-08-04 | Cantor Fitzgerald | Maintains | Overweight | $590 → $595 |
| 2026-08-04 | Canaccord Genuity | Maintains | Hold | $436 → $442 |
| 2026-07-13 | UBS | Maintains | Buy | $545 → $585 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 1.0% below the 50-day MA ($522.94).
- bullish: Price vs 200-day MA: Trading 8.3% above the 200-day MA ($477.61).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.88) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($409.47) and high ($557.96).
VRTX Price Chart
Loading chart for VRTX…
Fundamentals
About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
More in Biotechnology
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 29.9% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.